Sputum changes associated with the use of ipratropium bromide.
Long-term effects of ipratropium bromide (IB) were evaluated using a double-blind cross-over design in 23 adult chronic bronchitic participants. Two 20-micrograms doses of either IB or placebo were administered as an inhalant four times a day for a period of seven weeks. Sputum volume expectorated during a 24-hour period decreased significantly (p less than 0.05) over the entire length of the study, but sputum viscosity or its dry weight were not affected. Although total number of inflammatory cells in sputum was decreased by the use of IB (p less than 0.05), macrophages increased slightly. Subjects coughed less while receiving IB, and their cough was less severe (p less than 0.05). Ipratropium bromide caused a significant improvement (p less than 0.05) in the mechanics of breathing primarily in the subjects between 46 to 55 years of age. No major adverse reaction to IB was recorded.
D000328:Adult; D000368:Aged; D001286:Atropine Derivatives / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy*; D004311:Double-Blind Method; D004341:Drug Evaluation; D004804:Eosinophils / Q000032:analysis; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000032:analysis; D012129:Respiratory Function Tests; D013183:Sputum / Q000032:analysis / Q000187:drug effects*
D001286:Atropine Derivatives; D009241:Ipratropium